Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

PRINCETON, N.J., Jan. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.  

Pipeline Update and 2011 HighlightsPSI-7977In August 2010, we began dosing of PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a Phase 2b study. This study is evaluating PSI-7977 200mg QD, 400mg QD, or placebo in combination with Peg-IFN/RBV in approximately 125 treatment-naive patients with HCV genotype 1 (GT1), and PSI-7977 400mg QD with Peg-IFN/RBV in an open-label arm in patients with HCV GT2 or GT3. HCV GT1 patients receive an RVR-directed regimen of 12 weeks of PSI-7977/Peg-IFN/RBV followed by 12 or 36 weeks of Peg-IFN/RBV. The HCV GT2/3 patients receive 12 weeks of PSI-7977/Peg-IFN/RBV with no additional therapy.  The primary goal of the study is to assess the safety and tolerability of PSI-7977 in combination with Peg-IFN/RBV for 12 weeks. The primary efficacy endpoint of the study is the proportion of patients who achieve SVR12 and SVR24, defined as HCV RNA below the limit of detection (<15 IU/ml) 12 and 24 weeks, respectively, after the discontinuation of all therapy. Enrollment of this Phase 2b trial has been completed.

Twenty five treatment-naive patients with HCV GT2/3 patients were enrolled in the open label arm.  24/25 patients completed 12 weeks of PSI-7977 400mg QD with Peg-IFN/RBV; one patient was lost to follow-up after the first visit. A preliminary analysis of all data available at the end of 12 weeks of dosing revealed no serious adverse events and no discontinuations due to adverse events. The most commonly reported adverse events (AEs) overall were nausea, headache, chills, and f
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... of pharmaceutical marketing and, consequently, organizations are turning ... for patients. As part of this ... it,s important to educate, communicate and engage patients ... disease awareness to patient empowerment. By mapping the ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... 2011 A letter sent by a commercial insurer ... drug use when combining anti-clotting drug clopidogrel (Plavix®) with ... in the number of members combining the drugs, according ... leader Prime Therapeutics (Prime). Details of the study will ...
... PHOENIX, April 18, 2011 Altitude Organic Corporation ... company, announced today that it has launched its ... Scottsdale headquarters.  Visit the DoctorMMJ.com website ( www.DoctorMMJ.com ... professional, and entirely legal medical marijuana evaluation in ...
Cached Medicine Technology:Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 3
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace wedding ... the company has announced its new selection of elegant ... these outfits are available at discounted prices (from 25 ... is now offering similar discounts for many other wonderful ... other designs for sale, including flower girl dresses, wedding ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the innovative ... http://www.HealthYourself101.com will expand people’s understanding of the causes, consequences, ... out to provide a health education platform on this modern ... say it? – entertaining to dig into and learn from. ... remote learner – the solitary individual signing on from a ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, Fadhits.com, a ... collection of elegant long graduation dresses to its ... promotion for its loyal clients. It wants to bring more ... items are now offered at discounted prices, up to 72% ... company is always working hard. Its online shop is a ...
(Date:7/12/2014)... The rise in the number of mobility devices around ... to suit the upsurge. Virtualization has become a growing ... technologies. The data traffic has increased by several folds ... resulted in larger and more complex networks. These global ... market. , The North American (NA) region is expected ...
Breaking Medicine News(10 mins):Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5
... of ethnicity, U.S. study finds , , WEDNESDAY, Nov. 19 ... in the United States is roughly the same no ... study finds. , "Ethnic disparities in our health care ... diseases, such as coronary artery disease, congestive heart failure, ...
... Nov. 19 Scott P. Serota, President and Chief Executive ... released the following statement: , , ... companies have been steadfast champions of comprehensive healthcare reform to ... to improve quality throughout the entire system. We are pleased ...
... Today talk show host, Larry King,turns 75. In conjunction ... Health Solutions and the LAC+USC Camino de Salud Network,celebrated ... Angeles. The,Foundation, which provides cardiac diagnostics and helps pay ... trouble. In 1987, King suffered a heart,attack, one that ...
... Program to Educate Health Care Stakeholders , ... 19 The Virginia Business Coalition on Health (VBCH) ... payment reform efforts initiated by the Center for Medicare ... specific "Never Events" - serious and costly preventable hospital ...
... and Company recently,unveiled a free pocket-sized health book, A Healthy ... resources to help Americans lead a,healthy life and prevent chronic ... state of Ohio are distributing the book,to educate Ohioans with ... "A Healthy You! -- ...
... one third of all people who,suffer from a stroke, ... to doctors. Atrial fibrillation (AF), or an irregular ... of these cases. , ... Pittsburgh today,are reporting in the journal Neurology,( http://www.neurology.org/cgi/content/abstract/71/21/1696 ) ...
Cached Medicine News:Health News:Patient's Race Doesn't Affect Emergency Room Care 2Health News:BCBSA Announces Support for Individual Mandate Coupled With a Requirement for Insurers to Offer Coverage to All 2Health News:The King of Hearts Helps Others Follow a Healthy Road 2Health News:The King of Hearts Helps Others Follow a Healthy Road 3Health News:The King of Hearts Helps Others Follow a Healthy Road 4Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 2Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 3Health News:Lilly Offers Free Health Guide, Available throughout State 2Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 2Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: